| Management |
Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen alcohol androgens and anabolic steroids antituberculous agents azole antifungal agents ACE inhibitors disulfiram endothelin receptor antagonists interferons ketolide and macrolide antibiotics kinase inhibitors minocycline nonsteroidal anti-inflammatory agents nucleoside reverse transcriptase inhibitors proteasome inhibitors retinoids sulfonamides tamoxifen thiazolidinediones tolvaptan vincristine zileuton anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. |
